Single-dose respiratory mucosal delivery of next-generation viral-vectored COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2
Preprint
- 19 July 2021
- preprint
- research article
- Published by Cold Spring Harbor Laboratory
Abstract
Summary: The emerging SARS-CoV-2 variants of concern (VOC) increasingly threaten the effectiveness of current first-generation COVID-19 vaccines that are administered intramuscularly and are designed to only target the spike protein. There is thus a pressing need to develop next-generation vaccine strategies to provide more broad and long-lasting protection. By using adenoviral vectors (Ad) of human and chimpanzee origin, we developed Ad-vectored trivalent COVID-19 vaccines expressing Spike-1, Nucleocapsid and RdRp antigens and evaluated them following single-dose intramuscular or intranasal immunization in murine models. We show that respiratory mucosal immunization, particularly with chimpanzee Ad-vectored vaccine, is superior to intramuscular immunization in induction of the three-arm immunity, consisting of local and systemic antibody responses, mucosal tissue-resident memory T cells, and mucosal trained innate immunity. We further show that single-dose intranasal immunization provides robust protection against not only the ancestral strain of SARS-CoV-2, but also two emerging VOC, B.1.1.7 and B.1.351. Our findings indicate that single-dose respiratory mucosal delivery of an Ad-vectored multivalent vaccine represents an effective next-generation COVID-19 vaccine strategy against current and future VOC. This strategy has great potential to be used not only to boost first-generation vaccine-induced immunity but also to expand the breadth of protective T cell immunity at the respiratory mucosa.Keywords
Other Versions
- Published version: Version Cell, 185, preprints
This publication has 71 references indexed in Scilit:
- Airway Memory CD4 + T Cells Mediate Protective Immunity against Emerging Respiratory CoronavirusesImmunity, 2016
- Novel chimpanzee adenovirus-vectored respiratory mucosal tuberculosis vaccine: overcoming local anti-human adenovirus immunity for potent TB protectionMucosal Immunology, 2015
- Mucosal immunity and novel tuberculosis vaccine strategies: route of immunisation-determined T-cell homing to restricted lung mucosal compartmentsEuropean Respiratory Review, 2015
- Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trialThe Lancet Infectious Diseases, 2014
- Alveolar Macrophages Are Essential for Protection from Respiratory Failure and Associated Morbidity following Influenza Virus InfectionPLoS Pathogens, 2014
- Deletion and anergy of polyclonal B cells specific for ubiquitous membrane-bound self-antigenThe Journal of Experimental Medicine, 2012
- What Role Does the Route of Immunization Play in the Generation of Protective Immunity against Mucosal Pathogens?The Journal of Immunology, 2009
- Alveolar Macrophages Are the Primary Interferon-α Producer in Pulmonary Infection with RNA VirusesImmunity, 2007
- Exosomal vaccines containing the S protein of the SARS coronavirus induce high levels of neutralizing antibodiesVirology, 2007
- Mucosal vaccines: the promise and the challengeNature Reviews Immunology, 2006